Reported by Weng Patrick Atokor | journalist at wengglobal
The Democratic Republic of the Congo (DRC) has begun an unprecedented clinical trial aimed at identifying the first effective treatment for the Bundibugyo strain of the Ebola virus, marking a major milestone in the global fight against one of Africa’s most serious public health emergencies.
The World Health Organization (WHO), in collaboration with the DRC’s National Institute for Biomedical Research (INRB), the University of Oxford, the Institute of Tropical Medicine in Belgium, and Africa CDC, announced that the first patients have been enrolled in the PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) study. The initiative seeks to evaluate whether existing antiviral medicines can significantly reduce deaths caused by the rare Bundibugyo virus disease.
Unlike the more common Zaire strain of Ebola, for which approved vaccines and treatments exist, the Bundibugyo variant currently has no licensed vaccine or proven therapeutic treatment. Health experts believe the new trial could become a turning point in addressing not only the ongoing outbreak in eastern Congo but also future epidemics involving the same virus.
The clinical trial will evaluate two promising antiviral therapies—MBP134, an experimental monoclonal antibody, and the antiviral drug remdesivir. Researchers will assess each treatment individually, in combination, and alongside standard supportive care to determine which approach delivers the best outcomes for patients. More than 1,000 participants are expected to be enrolled over the coming months.
WHO Director-General Dr. Tedros Adhanom Ghebreyesus described the trial as a significant scientific achievement, noting that researchers, health authorities and international partners established the programme in record time despite operating in one of the world’s most challenging humanitarian environments. According to WHO, patients enrolled in the study will receive intensive monitoring and medical support for at least 28 days after joining the trial.
The urgency behind the research reflects the rapid expansion of the outbreak. WHO says the epidemic remains in an active growth phase, with infections continuing to spread across multiple provinces. Health authorities have warned that population movement, insecurity, limited healthcare infrastructure and delayed access to treatment continue to complicate containment efforts.
Recent data indicate that the outbreak has infected well over 1,700 people and claimed hundreds of lives, making it one of the largest outbreaks caused by the Bundibugyo virus. Experts caution that the true number of infections could be even higher because insecurity and logistical challenges make surveillance difficult in several affected communities.
Healthcare workers remain among those at greatest risk. Medical facilities in affected provinces have struggled with shortages of protective equipment, limited bed capacity and staffing constraints. Some response workers have staged protests over delayed salaries, highlighting operational difficulties facing the response despite continued international support.
Violence and mistrust have also undermined containment efforts. WHO officials have repeatedly warned that attacks on treatment centres and misinformation circulating within communities have slowed contact tracing, delayed treatment and discouraged some patients from seeking medical care early. Public health experts stress that community engagement remains just as important as scientific advances in bringing the outbreak under control.
The outbreak has attracted global attention after cases crossed international borders and foreign humanitarian workers were infected while supporting response operations. International health agencies continue to monitor the situation closely to prevent wider regional transmission.
Medical researchers believe successful results from the PARTNERS trial could reshape Ebola treatment worldwide. While vaccines have significantly reduced deaths from some Ebola strains, the Bundibugyo variant has remained a major scientific challenge because approved therapies have not previously been available.
The WHO has emphasized that the trial represents not only an emergency response but also an investment in long-term epidemic preparedness. Scientists hope the findings will provide evidence-based guidance that can save lives during future outbreaks and strengthen global health security.
Although optimism surrounding the trial is growing, experts caution that scientific evaluation takes time. Researchers will continue monitoring patients carefully before determining whether either treatment—or a combination of therapies—offers a statistically significant survival benefit.
For now, health authorities continue to urge communities in affected regions to report symptoms early, cooperate with contact tracing teams and follow infection prevention measures while scientists work toward identifying the first effective treatment for Bundibugyo Ebola.
Sources: World Health Organization (WHO); Reuters; The Guardian; Associated Press (AP); Africa CDC.
